CAPR vs VRTX
CAPR: Capricor is a clinical-stage biotech developing cell and exosome therapies for rare genetic disorders, with its lead candidate Deramiocel under FDA review for Duchenne muscular dystrophy treatment. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | CAPR | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $7.00 | $479.00 | |
| Market cap as of 2026-08-01 | $223M | $121.6B | |
| P/E as of 2026-08-01 | n/a | 27.78 | |
| PEG as of 2026-08-01 | -0.03 | 2.28 | CAPR lower |
| Net margin as of 2026-08-01 | -181.7% | +35.5% | VRTX higher |
| Gross margin as of 2026-08-01 | n/a | +86.2% | |
| Operating margin as of 2026-08-01 | -191.1% | +38.3% | VRTX higher |
| ROE as of 2026-08-01 | -59.3% | +23.9% | VRTX higher |
| ROA as of 2026-08-01 | -48.6% | +17.2% | VRTX higher |
| Debt / equity as of 2026-08-01 | 0.02 | 0.01 | VRTX lower |
| Revenue growth (YoY) as of 2026-08-01 | n/a | +10.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +10.4% | |
| Beta as of 2026-08-01 | 0.47 | 0.30 | |
| 1-year return as of 2026-07-27 close | -0.8% | +2.0% | VRTX higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.